Skip to main content
. 2015 Dec 6;2016:1602083. doi: 10.1155/2016/1602083

Table 2.

MACE among the study patients in the mean 2.3-year follow-up (n, %).

Control group
(n = 64)
Acarbose group
(n = 60)
Cardiovascular death, n (%) 5 (7.81) 3 (5.00)
Nonfatal reinfarction, n (%) 7 (10.94) 2 (3.33)
New-onset angina, n (%) 9 (14.06) 5 (8.33)
Cerebral stroke, n (%) 4 (6.25) 2 (3.33)
Severe heart failure, n (%) 5 (7.81) 4 (6.67)
Total MACE, n (%) 30 (46.88) 16 (26.67)

MACE: major adverse cardiovascular events.